Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE) [Gynecologic Cancer]

Conclusion
Although the primary objective was not met, subgroup analyses showed trends in PFS favoring pertuzumab in the gemcitabine and paclitaxel cohorts, meriting further exploration of pertuzumab in ovarian cancer.

Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Kurzeder, Bover, Marme, Rau, Pautier, Colombo, Lorusso, Ottevanger, Bjurberg, Marth, Barretina-Ginesta, Vergote, Floquet, del Campo, Mahner, Bastiere-Truchot, Martin, Oestergaard, Kiermaier, Schade-Brittinger, Polleis, du Bois, Gonzalez-Martin Tags: Chemotherapy, Combined Modality Gynecologic Cancer Source Type: research